Last reviewed · How we verify
Merrem
Merrem, marketed by the National Institutes of Health Clinical Center, is indicated for the treatment of abdominal abscess. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the lack of revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Merrem |
|---|---|
| Sponsor | National Institutes of Health Clinical Center (CC) |
| Target | Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Abdominal abscess
- Bacterial meningitis
- Bacteroides Complicated Appendicitis
- Bacteroides Peritonitis
- Complicated Skin and Skin Structure Infection
- Complicated appendicitis
- E. Coli Complicated Appendicitis
- E. Coli Peritonitis
- H. Influenzae Meningitis
- Infection due to Pseudomonas aeruginosa
- Infectious disease of abdomen
- Klebsiella Complicated Appendicitis
- Klebsiella Pneumoniae Peritonitis
- Neisseria meningitidis meningitis
- Peptostreptococcus Complicated Appendicitis
- Peptostreptococcus Peritonitis
- Peritonitis
- Pneumococcal meningitis
- Pseudomonas Aeruginosa Complicated Appendicitis
- Streptococcal Peritonitis
Common side effects
Key clinical trials
- Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1, PHASE2)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Merrem CI brief — competitive landscape report
- Merrem updates RSS · CI watch RSS
- National Institutes of Health Clinical Center (CC) portfolio CI